We also compared the antifibrotic activity of PDE4 inhibition to the two therapies that are FDA‐approved for idiopathic pulmonary fibrosis (pirfenidone and nintedanib). This evidence concerns the gene PDE4A and idiopathic pulmonary fibrosis.